Zoetis.co.uk uses cookies to improve your experience when browsing our website. By continuing to use this site, you are agreeing to their use. To find out more, view our cookie policy.

United Kingdom
Apoquel Logo

REFERENCES

 

1Apoquel SPC

2Zoetis study:A161-AU-12-096

3Zoetis Study: 1962C-60-09-930 , Cosgrove SB et al, Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis Vet Dermatol 2013; 24: 479–e114 (control of itch within 24hours)

4Zoetis study: Zoetis Study 1962C-60-10-A16 , Cosgrove SB et al, A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587-e142.

5Zoetis Studies: 5962C-85-08-364

6Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297

7Marsella R et al, Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. JAVMA, Vol 241, No. 2, July 15, 2012

8Fleck T et al, Comparison of the onset and anti-pruritic activity of the JAK inhibitor oclacitinib to prednisolone and dexamethasone in an IL-31 canine model of pruritus. Zoetis Study, Study A160R-US-12-057. Abstract NAVDF 2013 Louisville

9Fleck et al., WCVD 2012. Comparison of the janus kinase (JAK) inhibitor oclacitinib and prednisolone in canine models of pruritus. Vet Dermatol 2012; Jul;23(Suppl. 1): FC-36, p38

10Cosgrove SB et al, BSAVA 2014 [Abstract].Efficacy and safety of APOQUEL® (oclacitinib) administered to client-owned dogs enrolled in a long term compassionate care program.

11Zoetis study:1962C-60-10-A02.